Glycoconjugates containing polysialic acid have many biological activities and represent target molecules for therapeutic interventions. Enzymatic synthesis of these glycoconjugates should give access to these important molecules to evaluate their potential. The polysialyltransferases from both Neisseria meningitidis and Escherichia coli were cloned and expressed as recombinant proteins in E. coli. We have used synthetic acceptors to probe the acceptor requirement of these enzymes and to examine the basic enzymology. The minimum number of sialic acid residues (Neu5Ac) on the acceptor for activity in vitro was shown to be 2 for both enzymes, but a large increase in activity was seen if the acceptor had three Neu5Ac residues. The polysialyltransferase from N. meningitidis generated longer reaction products than the enzyme from E. coli on FCHASE acceptors. Examination of the products showed them to be a heterogeneous mixture, but products with >50 Neu5Ac residues could be seen using capillary zone electrophoresis analyses. In addition we made fusion proteins of these polysialyltransferase enzymes with the bifunctional α-2,3/α-2,8-sialyltransferase from Campylobacter jejuni to create self priming polysialyltransferases. These bifunctional sialyltransferases utilized various synthetic disaccharide acceptors with a terminal galactose, and we demonstrate here that the PST enzyme from N. meningitidis and its fusion protein with the C. jejuni sialyltransferase can be used to create polysialic acid on O-linked glycopeptides.
Introduction
Some bacterial pathogens that invade the mammalian host have taken advantage of the presence of sialic acid glycoconjugates on the host. These bacteria display some of these same carbohydrate chains on bacterial cell surfaces, and indeed a role for these carbohydrates in pathogenesis has been 1 To whom correspondence should be addressed: Tel: +1-613-952-4299; Fax: +1-613-941-1327; e-mail: warren.wakarchuk@nrc-cnrc.gc.ca demonstrated (Moran et al. 1996; Kahler and Stephens 1998) . Capsular polysaccharides from group B Neisseria meningitidis, Escherichia coli K1, Moraxella nonliquifaciens, and Mannheimia haemolytica A2 (formerly known as Pasteurella haemolytica A2) include sialic acid homopolymers of α-2,8-linked Neu5Ac. This is a molecular mimic of the mammalian polysialic acid (PSA) structure seen mainly on the neural cell adhesion molecule (NCAM), a brain specific protein integral to neuronal function. Other bacterial capsules have variations of PSA such as homopolymers of α-2,9-linked residues, copolymers in which the linkage is mixed α-2,8/α-2,9, and finally polymers in which other sugars are included, as in the group B Streptococcus agalactiae, N. meningitidis group Y and W (Table I) . It is thought that the presence of these carbohydrate mimics allows the pathogens to escape detection by the immune system since these molecules are not considered foreign. Further, the presence of these carbohydrates presents a physical barrier for the killing action of serum complement (Vogel et al. 1996) . The α-2,8-polysialic acid capsules are also required for crossing the blood-brain barrier to cause neuroinvasive disease in the case of E. coli, N. meningitidis, and the animal pathogen M. haemolytica (Silver and Vimr 1990) .
Because of the prominent role of these sialylated oligosaccharides in the biology of both the pathogen and the host, the enzymes involved in their biosynthesis in bacterial pathogens and in humans represent potential targets for therapeutic intervention and catalysts to produce biologically active glycoconjugates. For example, the homopolymer of α-2,9-linked Neu5Ac residues can be used as a vaccine for protection against group C meningococci (Girard et al. 2006) , and efforts are underway to develop such a vaccine based on the group B meningococcal homopolymer of α-2,8-linked Neu5Ac (Pon et al. 1997) . Recently it has been shown that the chemical coupling of α-2,8-polysialic acid to therapeutic proteins can extend their half-life in vivo, making them in effect more potent (Gregoriadis et al. 2005) . Additionally, the role of PSA in repair of the central nervous system has been examined in the context of using gene transfer to stimulate the production of PSA-NCAM and thus the regeneration of CNS axons (Franz et al. 2005; El Maarouf et al. 2006 ). Access to all of these PSA conjugates would be improved if their in vitro synthesis could be optimized with suitable enzymes.
To date there has been little detailed work on the fundamental aspects of sialyltransferase enzymology from bacterial pathogens. We and others (Gilbert et al. 1996; 2000; Chiu et al. 2004; Yu et al. 2005 ) have shown that it is possible to express, purify, and crystallize some of those enzymes responsible for lipooligosaccharise (LOS) sialylation. However no such work has been done with the enzymes involved in the generation of the sialic acid homopolymeric capsules. The genetic loci for the L M Willis et al. >4-Neu5Ac(7/8-OAc)-α-2,6-Gal-α-1-> (Jennings et al. 1977 ) Streptococcus agalactiae α-2,3-sialyl-lacto-N-neotetraose (Kogan et al. 1996) PSA capsule production have been identified in both E. coli and N. meningitidis, and some work has been done on the recombinant enzymes (NeuS) from E. coli K1, and K92 (Cho and Troy 1994; Shen et al. 1999 ), but again no detailed enzymology on the isolated sialyltransferase has been reported. The study of the enzymology has been hampered by the inability to isolate soluble enzyme and the lack of a simple synthetic acceptor from which enzymology data could be obtained. We have been able to clone active fusion proteins of both the E. coli K1 and N. meningitidis group B PST enzymes. We report here the characterization of the isolated recombinant enzymes using synthetic acceptors generated chemi-enzymatically. We also present data on a multifunctional fusion protein which functions as a self-priming polysialyltransferase that has potential for the in vitro synthesis of various PSA glycoconjugates which may be of therapeutic use.
Results

Comparison of N. meningitidis and E. coli polysialyltransferases
Both the genes for these polysialyltransferases are from the glycosyltransferase family GT-38 (Coutinho et al. 2003 ) which contains only bacterial members. The two proteins show only 33% identity ( Figure 1 ) even though they make identical structures in vivo. The proteins were expressed by themselves and as (Figure 2 ). The activity of the enzymes was determined using the synthetic acceptors derived from lactose-aminophenyl-(6-(5-(fluorescein-carboxamido)-hexanoic acid amide) (Lac-FCHASE), GM3-FCHASE, GD3-FCHASE, GT3-FCHASE, and GQ3-FCHASE (Table II) . These acceptors are named for the carbohydrate portion of the glycoside which resembles the head of a ganglioside. The enzymatic synthesis of these types of acceptors has been described previously (Blixt et al. 2005) . With these substrates the activity of these enzymes was shown to increase upon changing the number of Neu5Ac residues from 2 to 3. With the PST Nm enzyme the specific activity increased threefold comparing GT3-FCHASE with GD3-FCHASE. There was no detectable activity when only one Neu5Ac residue was present. In our hands the Neisseria enzyme is more active toward these small synthetic substrates than the E. coli enzyme; in fact, we saw only oligosialic acid production and never saw long polymers with the PST Ec construct so we focused our efforts on the Neisseria enzyme (PST Nm ). 
PST does not appear to follow Michaelis-Menten kinetics when using a CE-based assay
We made several attempts to measure kinetic parameters of PST Ec and PST Nm using the synthetic acceptors described above. The CE-based assay however does not permit the determination of substrate interconversion during the assays. Hence we could only follow the production of all products as a function of their combined peak area on electropherograms ( Figure 3 ), but we could not look at specific products formed as the result of generating a better acceptor as the reaction proceeded. Trying to fit these data with the Michaelis-Menten equation did not show a very good fit ( Figure 4 ). For this reason we were only able to estimate the apparent K m for GD3-FCHASE as 120 µM with PST Nm and 145 µM with PST Ec , along with an apparent K m for CMP-Neu5Ac of 1.4 mM for PST Nm and 3.2 mM for PST Ec . When performing assays to examine kinetic parameters, we found that PST Nm showed acceptor inhibition with higher concentrations of GD3-FCHASE. At concentrations over 2 mM the productivity of the enzyme decreased significantly (data not shown). In some experiments we observed degradation of the starting material, which was more significant at high acceptor concentrations (5 mM), but this was not always reproducible.
Addition of Mg
2+ results in a fourfold increase in the activity of PST Nm In order to ensure the best possible activity, assays were optimized for metal and buffer composition and pH optimum. The enzyme showed a broad pH optimum, but had the highest activity around pH 8 (data not shown). The enzyme showed a strong preference for Mg 2+ compared to other divalent cations (data not shown). After removing endogenous metals by dialysis with EDTA, the enzyme was titrated with MgCl 2 to determine the optimum concentration required for activity. N. meningitidis PST exhibits a fourfold increase in activity with the addition of 20 mM MgCl 2 .
Functional characterization of the CST-PST fusion enzymes
In order to use PST as a synthetic tool, it is necessary to provide it with a primer of two sialic acid units. We chose to create a unique fusion protein with the CST-II enzyme from Campylobacter jejuni which can generate this primer. Fusions were made between the CST-II (Ile53Gly) from C. jejuni OH4384 (Gilbert et al. 2002) and both E. coli (CST-PST Ec ) and N. meningitidis (CST-PST Nm ) polysialyltransferases. We used both of the fusions and compared both Lac-FCHASE and L M Willis et al.
Fig. 3.
Representative capillary electrophoresis analysis of PST with a FCHASE-glycoside. A sample of an enzyme reaction with GD3-FCHASE was diluted to 2 µM in water and injected into a bare silica capillary which had been equilibrated in TBE buffer (89 mM Tris, 89 mM Boric acid, 2 mM EDTA pH 8.8). The samples were resolved at 30 kV with a PACE-MDQ equipped with an argon ion laser induced fluorescence detector (λ Ex 488 nm, with emission filter at 520 nm). Each peak corresponds to the addition of one Neu5Ac residue.
T-Ag-FCHASE in a time course assay ( Figure 5 ). Traces from these assays clearly show a qualitative difference in the product distribution between these CST-PST fusions. Even though the acceptor is consumed completely with CST-PST Ec , there are no long polymers formed that can be seen by CE analysis. With CST-PST Nm the formation of long polymers occurs from the earliest time points, and in longer reactions, products greater than DP-50 can be seen. This reflects the observation we made with the MalE fusion version of PST Ec that it does not make long polymers on FCHASE-aminophenylglycosides in vitro ( Figure 6 ).
The CST-PST Nm enzyme was shown to be a very good catalyst for making long polymers starting from simple galactosides. A comparison of acceptors was performed with lactose, N-acetyllactosamine, Gal-β-1,3-GalNAc-α (T-Ag) disaccharide acceptors, and two glycopeptide acceptors containing an O-linked Gal-β-1,3-GalNAc-α-Ser moiety. We observed that Lac-and LacNAc-FCHASE were equally good acceptors (data not shown), and that T-Ag-FCHASE was a slightly weaker acceptor. In a time course experiment with CST-PST Ec and CST-PST Nm we showed that with a single addition of enzyme and fixed donor concentration essentially all of the Lac-FCHASE is consumed but only 72% of the T-Ag material is consumed (data not shown). The glycopeptides were also very good acceptors for the CST-PST Nm fusion protein, and long PSA polymers could be seen in CE analysis of these reactions.
Production of CST-PST Ec and CST-PST Nm
Partial purification of the fusion proteins between CST-II and either PST was achieved by removing other proteins by binding them to a HiPrepQ FF column, followed by ammonium sulfate precipitation of the flow through fraction. It is not possible to know the exact level of enrichment, but using gel densitometry we showed that CST-PST represents around 12-14% of the total protein (Figure 2) . The protein can also be recovered by the ultracentrifugation of this flow through fraction. This would suggest that the enzyme is present as a micellar or aggregated preparation.
Comparison of the fusion protein with mixtures of the individual parent enzymes
In order to evaluate if the fusion protein functions more efficiently than the two parent enzymes mixed together we performed experiments where we controlled the stoichiometry of the individual sialyltransferases. Because the fusion protein could not be purified to homogeneity, we estimated how much enzyme was in the preparations with densitometry of SDS-PAGE analysis. We then made reaction mixtures with an equivalent amount of the purified parent enzymes (CST-II and PST Nm ). In this comparison (Figure 7 ), it appears that the fusion protein is a more efficient catalyst making more than four times as much polysialic acid product on the T-Ag-containing IFNα2b glycopeptide (20-40% PSA versus 3-4% PSA for the combination), and this is also shown with the monosialylated T-Ag-glycopeptide acceptor, although here only a twofold increase is seen (60-75% PSA versus 35-45% PSA). What is significant is that the level of disialylated intermediate is much higher in the reaction with the separate enzymes. We applied ANOVA (t-test) to the production of the PSA in these experiments and found that level of PSA formed in the different reactions with separate enzymes and those with the fusion was statistically significant. When the acceptor was the monosialylated T-Ag-glycopeptide acceptor P = 0.002 for PSA formation in this series of experiments. When the acceptor was T-Ag-containing IFNα2b glycopeptide P = 0.03 for PSA formation in this series of experiments. Another significant observation is that at very short reaction times, the fusion protein generates PSA material from both types of acceptors, whereas the separate enzymes do not. With longer incubation times CST-PST Nm will convert >50% of the T-Ag-glycopeptide to polysialylated product (Figure 7) , and if the peptide is already monosialylated then the reaction goes to ∼75% polysialylated material (data not shown). We have also used a second glycopeptide acceptor, this time derived from the O-linked glycosylation site of the granulocyte colony stimulating factor (G-CSF Thr-134) (DeFrees et al. 2006) . The data on the extent of the polysialylation of these two peptides are very similar so we have not shown all the data for both peptide acceptors.
Discussion
Polysialyltransferases are found in both humans and some human bacterial pathogens. The human PST enzymes are classified in the CAZY family GT-29 along with all the other human sialyltransferases because of the presence of various sialyl-motif sequences common to all mammalian sialyltransferases. The bacterial PST enzymes are found in a unique GT-38 family and are not sequence-related to any other sialyltransferases, and have no apparent sialyl-motif sequences. This difference in structures is accompanied by some fundamental changes in activity as well.
The human enzymes ST8SiaII (STX) and ST8SiaIV (PST) can effectively use α-2,3/2,6 monosialylated acceptors (Angata and Fukuda 2003) whereas the bacterial enzymes appear to have a minimal requirement for a glycan structure containing α-2,8-disialic acid as a primer for the reaction, although the in vivo primer structure is still not known. We felt it was important to revisit the minimal acceptor requirement to ensure our recombinant protein was not enzymatically compromised because of the nature of the protein fusion. There are conflicting reports about the mammalian enzymes having different divalent metal requirements and pH optima (Kitazume-Kawaguchi et al. 2001 and references within), but the PST Nm enzyme clearly has a requirement for Mg 2+ where it shows a fourfold increase in activity at 20 mM Mg 2+ and a slightly basic pH optimum. The cloning and expression of soluble forms of the human PST enzymes has been described in the literature for many years (see references in Angata and Fukuda 2003) , but so far large amount of the enzymes have not been available for in vitro synthesis of PSA containing glycoconjugates. Our expression and purification of the bacterial PST enzymes yields more active protein than has been seen for the mammalian enzymes, which has been the case for a number of bacterial enzymes which make human glycan structures (Gilbert et al. 1998; Blixt et al. 2001 Blixt et al. , 2005 . The ease of expression of many bacterial glycosyltransferases including the bacterial PST is likely due to the absence of critical disulfide bonds and the lack of posttranslational modification which are required for many eukaryotic glycosyltransferases (Datta et al. 2001; Uemura et al. 2005) .
The bacterial PSTs have been reported to be peripheral membrane proteins which have previously been found only in the membrane fraction as proteins, which we found were not active after solubilization with detergents (data not shown). We chose to use the MalE tag as it has been a useful solubilizing fusion partner for many of the glycosyltransferases we have studied, especially another sialyltransferase, LST, from N. meningitidis . While this fusion protein is not completely soluble at 100,000 × g, it can be isolated in multimilligram quantities and has been shown to be able to work very well in vitro for the acceptors we have tested so far. A recent manuscript (Freiberger et al. 2007 ) also describes a MalE fusion of the PST Nm and they have also shown the activity with our FCHASE-based acceptor. The MalE fusion produced in our laboratory has a slightly higher purity than described by Freiberger et al. (based on the SDS-PAGE profiles) and appears to be less soluble for reasons that are not clear at this time. Clearly some differences exist between the recombinant constructs and the method of enzyme preparation, which makes a direct comparison of these enzymes difficult. We have shown that the purified MalE fusion of the PST enzyme is stable enough to be stored for several weeks in the presence of glycerol at −20
• C which is another property that makes this enzyme much more accessible than the mammalian ST8SiaII/IV enzymes which have not been reported to be expressed in this quantity or as stable. The mammalian enzymes have been examined mainly as chimeras with the IgG-Fc fragment which are secreted and captured on beads and assayed in that way (Angata et al. 2004) .
When comparing the two bacterial PST enzymes, we found that the in vitro activity of the PST Ec was qualitatively different from the PST Nm in that we only ever saw short polymers with the PST Ec enzyme with our aminophenylglycoside-based synthetic acceptors. Both enzymes will however make polymers on the glycopeptide substrates we used, although the activity of PST Ec is again very weak (data not shown). Clearly in vivo long polymers are formed in both organisms, so the reason for this altered in vitro activity on the FCHASE-glycoside acceptors is not clear. There is some evidence that the PST Ec requires additional proteins in order to function as a PST in vivo (Andreishcheva and Vann 2006) which might explain its poor performance compared to the PST Nm. . The E. coli polysialic biosynthesis operon contains the NeuE protein which has been shown to be required for efficient polymer formation in vivo and to form a complex with NeuS (PST Ec ) as well as the capsule export protein KpsC/S. There are NeuE homologues in Neisseria as well, but their function has not yet been investigated. A rather more trivial explanation for the lower activity of the MalE fusion might be that it simply prevents the PST Ec from folding correctly, so that its activity is no longer optimal. This may be the case as recombinant NeuS has been shown to be fully capable of forming polymers on various acceptors when expressed as a membrane bound protein (Cho and Troy 1994) . This observation means that with both of these enzymes we may have the ability to form both shorter oligosialic acid chains and longer polymers. This opens the possibility of evaluating both types of chains for their contribution to the function of glycans.
We were unable to perform detailed kinetic assays on the PST enzyme due to the interconversion of acceptors during the assay and how we were detecting these products. What this means is that the products of the reaction are better substrates than the starting material, and therefore we cannot quantitate the level of conversion of all the products, just the starting material relative to all products. We have also investigated using the continuous assay described by Freiberger et al. (2007) , but in our hands, the background from concentrations of CMP-Neu5Ac over 0.5 mM prevented us from collecting data at higher donor concentrations. Using the CE-based assay we obtained a K m which is three-to fivefold higher than what they reported, which is reflected in the much higher activity we see with concentrations of CMP-Neu5Ac around 10 mM. We are planning to investigate modified CMP-Neu5Ac donors as chain terminators as a means of examining the acceptor binding when there is only one turn over event which eliminates the substrate interconversion. We have already examined the 9-O-acetyl sialic acid, which is a chain terminator, but this donor has the drawback that the O-acetyl group hydrolyses slowly during the reaction leading to a background level of polymeric material which makes the quantitation of product difficult (data not shown). A similar approach has been used to examine the K92 PST Ec where a 9-azido-NeuAc was used as a chain terminator to examine the alternating α-2,8/2,9 NeuAc linkage formed by this enzyme . Use of these modified NeuAc donors should provide data toward the understanding of the chemical mechanism of this class of enzymes.
Because of the requirement for the disialic acid acceptor we decided to investigate enzyme fusions with the bifunctional α-2,3/2,8 sialyltransferase from C. jejuni (CST-II). Our work with CST-II to make di-, and trisialylated ganglioside mimics made us think we could have a single polypeptide which could then produce polysialic acid from galactoside acceptors. There is no indication that Campylobacter has polysialic acid on any of its ganglioside mimics. Our first attempts to make such fusion proteins were successful, and we did compare the ability of both PST Ec and PST Nm to function in this construct. The CST-PST Nm fusion performed better than the CST-PST Ec fusion because of the PST Nm making longer polymers on our substrates. We investigated the ability of this fusion to make polysialylated material using a variety of simple disaccharide acceptors and showed that the nature of the linkage of the galactose containing acceptor had only a minimal effect on the activity of the enzyme. The Gal-β-1,3-GalNAc-α-R disaccharide is a typical O-linked glycan on many glycoproteins which would provide a convenient handle for the addition of sialic acid to the protein. We were able to show that with model glycopeptide acceptors with an O-linked disaccharide we could produce polysialylated material and the fusion does function better than the two proteins provided separately. However, we still need to improve the production of this fusion protein, as it is not as soluble as the MalE fusion of PST, and cannot yet be purified to homogeneity.
The work of Gregoriadis et al. (2005) has shown that the chemical coupling of preformed PSA chains can increase the circulating half-life of therapeutic proteins, but the addition depends on having available lysine residues, and not all residues are modified. The great advantage of using an enzyme is that we can control where the PSA will go, and this will permit the synthesis of PSA at defined sites in therapeutic proteins which are less likely to interfere with the function of that protein and are easier to characterize for regulatory agencies. Having shown that model glycopeptides are good acceptors we are now looking at in vitro protein polysialylation with these enzymes.
Material and methods
Bacterial strains, plasmids, and growth conditions N. meningitidis 992B NRCC4726, obtained from Dr. Harold Jennings, was grown on Columbia Blood Agar at 37
• C and 5% CO 2 . E. coli O18:K1:H7 LCDC 84-1743, obtained from Health Canada, was grown on 2YT plates at 37 • C. E. coli AD202 (CGSC 7297) was used for expression of cloned enzymes. Recombinant E. coli strains were grown in 2YT broth with 150 µg/mL ampicillin at 37
• C for 2 h and then induced with 0.5 mM isopropyl-1-thio-β-D-galactopyranoside and grown at 20
• C for 24 h. The plasmid used for cloning was a modified pCWori+ (Wakarchuk et al. 1994) . N-Terminal fusions to the maltose binding protein of E. coli were made using the plasmid pCWmalE-thrombin (this plasmid has a thrombin cleavage site between the MalE and the cloned polysialyltransferase). In this plasmid, the malE gene from E. coli (strain BMH-71-18) with an added thrombin recognition sequence at the 3 end was inserted at the NdeI site of pCW and the 5 NdeI site was changed to CAGATG, leaving the 3 site intact for subsequent cloning.
Basic recombinant DNA method All DNA isolations, restriction enzyme digestions, ligations, and transformations were performed as recommended by the supplier. Enzymes were obtained from New England Biolabs (Mississauga, ON, Canada). Genomic DNA was isolated using a DNeasy Tissue kit (Qiagen Inc., Mississauga, ON, Canada). PCR was performed using Phusion polymerase and the program: 94
• C for 5 min, 30 cycles of 94
• C for 30 s, 55
• C for 30 s, and 72
• C for 60 s, and finally 72
• C for 10 min. Primers for the E. coli PST were as follows: 5 -AAGGTATAAGACATATGA-TATTTGATGCTAGTTTAAAGAAG and 3 -CCTAGGTCGA-CTTACTCCCCCAAGAAAATCCTTTTATCGTGC. The N. meningitidis PST was amplified in two stages to remove an internal NdeI site (T474C). Two separate PCR reactions were performed to generate two overlapping gene fragments that both contained the silent mutation due to either the 5 or the 3 primers. The two PCR products were then used with primers 5 -GCTGGAGCTGGACATATGCTAAAGAAAATAAAAAA-AGCTCTTTTTCA and 3 -GCTGGAGCTGGAGTCGACCTA-TTATCTATCTCTACCAATTCTATTGTC to amplify the fulllength gene containing the silent mutation. DNA was purified using either Qiaquick or Minelute kits from Qiagen Inc. (Mississauga, ON). Genes digested with NdeI and SalI were ligated into pCW or pCWmalE-thrombin and then used to transform E. coli AD202 by electroporation. Plasmids were isolated using High Pure Plasmid Isolation kit (Roche Diagnostics, Laval, PQ, Canada). DNA sequencing was performed using an Applied Biosystems (Montreal, PQ, Canada) model 3100 automated DNA sequencer and the manufacturer's cycle sequencing kit.
Construction of CST-PST fusions
The CST used was from C. jejuni OH4384 and consists of the first 260 amino acids with the mutation I53S, which is known to stabilize the CST-II proteins (Chiu et al. 2004) . The gene was amplified with primers 5 -CTTAGGAGGTCATATGAAAAAA-GTTATTATTGCTGGAAATG which contains an NdeI site and 3 -GCTGGAGCTGGACATATGTCCGCCTCCAAAATTAAT-ATTTTTTGAAAATTTTCC which corresponds to the 3 end of CST without a stop codon, followed by three glycine codons to act as a linker and then an NdeI site. The pCWPST plasmids were digested with NdeI and then ligated with NdeI digested CST before transforming E. coli AD202 by electroporation. The orientation of the CST gene was determined with HindIII digestion and confirmed by sequencing.
